Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene…


Clear evidence of SERPINA1 gene delivery and AAT expression following KB408 administration in AATD patients

More here:
Krystal Biotech Announces Initial Clinical Update for Rare Respiratory Disease Programs KB408 and KB407 Including Early Clinical Evidence of Gene...

Related Posts